Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Thiogenesis Therapeutics Corp TTIPF


Primary Symbol: V.TTI

Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. It is the active ingredient used in drugs to treat the lysosomal storage disease - (nephropathic) cystinosis. TTI-0102 has been developed to address the obstacles facing thiol-based drugs, their short half-life, gastrointestinal (GI) side effects and dosing limitations. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism. TTI-0102’s initial applications are for MELAS, Leigh syndrome, Rett syndrome and pediatric non-alcoholic steatohepatitis (NASH).


TSXV:TTI - Post by User

User Avatar Image
(131)
•••
  • 1StockInformerX
Post by 1StockInformeron Jan 07, 2025 7:32pm
31 Views
Post# 36393385

TTI Targets Multi-Billion Dollar Markets, Advancing Trials

TTI Targets Multi-Billion Dollar Markets, Advancing Trials

Thiogenesis Therapeutics Corp. (Ticker: TTI.v) is a clinical-stage biopharmaceutical company focused on developing thiol-active therapeutic compounds to address mitochondrial dysfunctions with high unmet medical needs. 

A recent financial analysis from Valuation Lab, published on December 16, 2024, highlights the company’s lead compound, TTI-0102, and its potential across multiple pediatric and orphan indications.

https://www.valuationlab.com/research/

TTI-0102 is a prodrug designed to address limitations associated with cysteamine, a treatment for cystinosis. It is being developed for four key indications: MELAS, Leigh syndrome, Rett syndrome, and pediatric MASH. 

These conditions represent significant market opportunities, with global peak sales projected to reach CAD 9.8 billion. 

Key catalysts for 2025 include the start of Phase II proof-of-concept (POC) trials:

  • MELAS (Q1 2025): Potential peak sales of CAD 4 billion and a 15% projected success rate upon trial initiation, raising the risk-adjusted net present value (rNPV) by CAD 10.6 per share.  

  • Leigh Syndrome (H1 2025): An ultra-rare condition with no approved treatments, projected peak sales of CAD 40 million, and a similar 15% success rate assumption, potentially increasing rNPV by CAD 0.1 per share.  

  • Pediatric MASH (H1 2025): A larger market opportunity, with peak sales estimates of CAD 4 billion, and a projected rNPV increase of CAD 1.6 per share following trial commencement.

r/Wallstreetbetsnew - Financial Analysis Summary: Thiogenesis Therapeutics (TTI.v) Targets Multi-Billion Dollar Markets with Lead Drug, Advancing Phase II Trials in 2025 for MELAS, Leigh Syndrome, and Pediatric MASH

Valuation Lab assigns a risk-adjusted sum-of-parts valuation of CAD 7.5 per share, with MELAS accounting for 65% of this value. 

Significant progress was made in 2024, including securing a European patent for TTI-0102 with protection until 2037, collaborations with research institutions, and regulatory approvals for clinical trials. These developments bolster the company’s intellectual property position and clinical readiness.

With plans to achieve break-even by 2026, Thiogenesis intends to commercialize orphan indications through contract sales organizations while seeking licensing deals for larger indications like pediatric MASH. This approach aims to maximize value while reducing upfront costs.

In summary, Thiogenesis Therapeutics is advancing TTI-0102 as a multi-indication pipeline with substantial market potential. Its focus on pediatric and orphan diseases, supported by strong intellectual property and expedited regulatory pathways, positions it for significant growth pending clinical milestones.

Download the full report here: https://www.valuationlab.com/app/download/8229158562/vL+Thiogenesis+Flash+Update+16DEC24.pdf

Posted on behalf of Thiogenesis Therapeutics Corp.

<< Previous
Bullboard Posts
Next >>